Literature DB >> 10930674

Identification of a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), targeted by human antibodies mediating parasite killing.

M Theisen1, S Soe, S G Jessing, L M Okkels, S Danielsen, C Oeuvray, P Druilhe, S Jepsen.   

Abstract

The antigenicity of the glutamate-rich protein (GLURP) of Plasmodium falciparum was comprehensively evaluated in epitope-mapping studies utilizing a phage display library, synthetic peptides and anti-GLURP IgG preparations previously shown to promote strong antibody-dependent cellular inhibition (ADCI) effects. We identified six major B-cell epitopes within the nonrepetitive region R0, corresponding to amino acid residues 173 to 187 (P1), 193 to 207 (P3), 216 to 229 (P4), 264 to 288 (P11), 343 to 357 (P10), and 407 to 434 (S3). Of these, four (P1, P3, P4, and S3) were frequently recognized by high-titered IgG antibodies in plasma samples from immune Liberian adults (prevalence: 29.1-45.0%). The three epitopes P1, P3, and P4 contained a common motif (seven out of nine positions are identical) and may thus constitute a family of structurally related epitopes. This leaves two distinct epitopes, one (P3) representing this new epitope family and S3 as targets for biologically active antibodies. Human IgG antibodies from single plasma samples were affinity-purified against these peptides. P3-specific IgG preparations were consistently more effective in ADCI than S3-specific IgG. Among the different GLURP epitopes, we therefore suggest that the P3 epitope is potentially the most important epitope in GLURP for the development of clinical immunity to malaria in man.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10930674     DOI: 10.1016/s0264-410x(00)00181-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans.

Authors:  Corine G Demanga; Lena-Juliette Daher; Eric Prieur; Catherine Blanc; Jean-Louis Pérignon; Hasnaa Bouharoun-Tayoun; Pierre Druilhe
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

2.  Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria.

Authors:  Anja Jäschke; Boubacar Coulibaly; Edmond J Remarque; Hermann Bujard; Christian Epp
Journal:  Clin Vaccine Immunol       Date:  2017-11-06

3.  High-density Peptide Arrays Help to Identify Linear Immunogenic B-cell Epitopes in Individuals Naturally Exposed to Malaria Infection.

Authors:  Thomas Jaenisch; Kirsten Heiss; Nico Fischer; Carolin Geiger; F Ralf Bischoff; Gerhard Moldenhauer; Leszek Rychlewski; Ali Sié; Boubacar Coulibaly; Peter H Seeberger; Lucjan S Wyrwicz; Frank Breitling; Felix F Loeffler
Journal:  Mol Cell Proteomics       Date:  2019-01-10       Impact factor: 5.911

4.  Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity.

Authors:  M Theisen; D Dodoo; A Toure-Balde; S Soe; G Corradin; K K Koram; J A Kurtzhals; L Hviid; T Theander; B Akanmori; M Ndiaye; P Druilhe
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

5.  New developments in malaria diagnostics: monoclonal antibodies against Plasmodium dihydrofolate reductase-thymidylate synthase, heme detoxification protein and glutamate rich protein.

Authors:  Johanna H Kattenberg; Inge Versteeg; Stephanie J Migchelsen; Iveth J González; Mark D Perkins; Petra F Mens; Henk D F H Schallig
Journal:  MAbs       Date:  2012 Jan-Feb       Impact factor: 5.857

6.  Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants.

Authors:  Leonardo J M Carvalho; Francisco A Alves; Cesare Bianco; Salma G Oliveira; Graziela M Zanini; Soe Soe; Pierre Druilhe; Michael Theisen; José A P C Muniz; Cláudio T Daniel-Ribeiro
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

7.  Understanding human-Plasmodium falciparum immune interactions uncovers the immunological role of worms.

Authors:  Christian Roussilhon; Philippe Brasseur; Patrice Agnamey; Jean-Louis Pérignon; Pierre Druilhe
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

8.  A multiplex assay for the simultaneous detection of antibodies against 15 Plasmodium falciparum and Anopheles gambiae saliva antigens.

Authors:  Elena Ambrosino; Chloé Dumoulin; Eve Orlandi-Pradines; Franck Remoue; Aissatou Toure-Baldé; Adama Tall; Jean Biram Sarr; Anne Poinsignon; Cheikh Sokhna; Karine Puget; Jean-François Trape; Aurélie Pascual; Pierre Druilhe; Thierry Fusai; Christophe Rogier
Journal:  Malar J       Date:  2010-11-08       Impact factor: 2.979

9.  Distinct patterns of blood-stage parasite antigens detected by plasma IgG subclasses from individuals with different level of exposure to Plasmodium falciparum infections.

Authors:  Cathrine Holm Olesen; Karima Brahimi; Brian Vandahl; Susana Lousada-Dietrich; Prajakta S Jogdand; Lasse S Vestergaard; Daniel Dodoo; Peter Højrup; Michael Christiansen; Severin Olesen Larsen; Subhash Singh; Michael Theisen
Journal:  Malar J       Date:  2010-10-26       Impact factor: 2.979

10.  A novel domain cassette identifies Plasmodium falciparum PfEMP1 proteins binding ICAM-1 and is a target of cross-reactive, adhesion-inhibitory antibodies.

Authors:  Anja Bengtsson; Louise Joergensen; Thomas S Rask; Rebecca W Olsen; Marianne A Andersen; Louise Turner; Thor G Theander; Lars Hviid; Matthew K Higgins; Alister Craig; Alan Brown; Anja T R Jensen
Journal:  J Immunol       Date:  2012-12-03       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.